11 Pharmaceuticals Stocks to Sell Now

11 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 11 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Novartis AG Sponsored ADR’s (NVS) rating worsens to a F from the company’s D rating a week ago. Novartis AG Sponsored ADR manufactures pharmaceutical and consumer healthcare products. For more information, get Portfolio Grader’s complete analysis of NVS stock.

Astrazeneca PLC Sponsored ADR’s (AZN) rating weakens this week, dropping to a D versus last week’s C. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Phibro Animal Health Corporation Class A (PAHC) is having a tough week. The company’s rating falls from a C to a D. For more information, get Portfolio Grader’s complete analysis of PAHC stock.

Catalent Inc (CTLT) declines this week from a C to a D. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of CTLT stock.

Slipping from a D to a F rating, Paratek Pharmaceuticals Inc (PRTK) takes a hit this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Zynerba Pharmaceuticals Inc (ZYNE) slips from a C to a D this week. The company also gets F’s in sales growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZYNE stock.

This week, Teligent, Inc. (TLGT) drops from a C to a D rating. The company also gets F’s in operating margin growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of TLGT stock.

Flex Pharma, Inc. (FLKS) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLKS stock.

This is a rough week for Nabriva Therapeutics AG Sponsored ADR (NBRV). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NBRV stock.

MediWound Ltd. (MDWD) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MDWD stock.

Acura Pharmaceuticals, Inc. (ACUR) earns a F this week, moving down from last week’s grade of D. Acura Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACUR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/11-pharmaceuticals-stocks-to-sell-now-3/.

©2020 InvestorPlace Media, LLC